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Abstract. The mechanistic complexes of kinase D-interacting 
substrate of 220 kDa/ankyrin repeat-rich membrane span-
ning (Kidins220/ARMS) bind and integrate a variety of 
cellular cues to mediate neuronal activities such as neuronal 
differentiation, survival, and cytoskeleton remodelling by 
interacting with a variety of binding partners. Accumulated 
evidence has also indicated its role in the regulation of vascular 
development. Mice with Kidins220 knockdown phenotypi-
cally present with cardiovascular abnormalities. Kidins220 
also contributes to immunomodulation in combination with 
B cells and T cells. Moreover, emerging evidence has revealed 
that this protein regulates many crucial cellular processes and 
thus has been implicated in an increasing number of malig-
nancies. Here, we review recent advances in our understanding 
of Kidins220 and its role in cancer development. Further 
investigation is warranted to shed light on the role played by 
Kidins220 in the dynamic arrangement of the cytoskeleton 
and epithelial–mesenchymal transition, and its implication in 
tumourigenesis and cancer progression.
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1. Introduction
Scaffold proteins have evolved for efficiently interacting with 
certain signalling pathways and maintaining cellular structure. 
This is achieved through the regulation of the cytoskeleton, 
cell adhesion, and migration, allowing cells to survive and 
grow in variable environments. Dysregulation of certain scaf-
fold proteins has been implicated in malignancies, including 
cancer development and metastasis. In mammals, an example 
of such multi-functional transmembrane scaffold proteins, is 
kinase D-interacting substrate of 220 kDa/ankyrin repeat-
rich membrane spanning (Kidins220/ARMS). Kidins220 is 
a highly conversed integral membrane protein, which was 
initially identified as a substrate for protein kinase D (PKD), 
a serine/threonine kinase responsible for regulation of several 
cell processes (1). Despite recent studies demonstrating the 
role of Kidins220 in neurotrophin response, it is increasing 
apparent that Kidins220 is involved in the regulation of 
many cellular functions. Dysregulation of Kidins220 occurs 
in several human diseases including neurodegeneration 
and cancer, and thus there is increasing effort to pharma-
cologically target this protein. Here, we review our current 
understanding of Kidins220 and further discuss the possible 
links of Kidins220 to malignancies.
2. Kidins220/ARMS
Initially discovered in the nervous systems, Kidins220 
responds to variable environment cues and coordinates 
neuronal survival, differentiation and plasticity (2-4). In 
the nervous system, Kidins220 is one of the downstream 
substrates for tropomyosin-related kinase (Trk) signalling (5). 
In mammal neural tissues, Kidins220 has a high binding 
affinity for neurotrophins and localizes to the tips of neurites 
abundant and enriched in expression of ephrin receptors 
and neurotrophins (6). In the nervous system, Kidins220 
acts as a platform for protein-protein interactions, where its 
multiple domains recruit downstream receptor substrates 
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resulting in the activation of signalling pathways which lead 
to neuronal differentiation, survival, cytoskeleton remodelling, 
synaptic plasticity and dendrite and synapse development (7). 
Development of the vascular system involves the interaction of 
Kidins220 with vascular endothelial growth factor receptors 
(VEGFRs). Knockout of Kidins220 resulted in impairment of 
the VEGF signalling pathway, while an in vivo study revealed 
that mice lacking Kidins220 developed cardiovascular abnor-
malities (8).
3. Kidins220 structure, expression and localization
The Kidins220 gene encodes a protein of 1715 amino acids. 
Kidins220 protein is comprised of 11 ankyrin-repeats within 
the N-terminal region, a proline-rich stretch, a sterile α 
motif (SAM) domain (9), kinase light chain (KLC)-interacting 
motif (KIM), and a PSD-95, Dlg, ZO-1-binding motif (PDZ) 
at its C-terminal. It contains four transmembrane segments in 
the central part of the molecule and N- and C-terminal tails 
both exposed to the cytoplasm. Kidins220 is the target of a 
molecule called protein kinase D, which first gained attention 
due to its broad regulation of neuronal properties. Biochemical 
processes led to the purification and identification of multiple 
Kidins220 domains which act as regulators in a variety of cell 
signalling pathways.
Originating from monocytes, immature dendritic cells in 
peripheral blood have been shown to express high levels of 
Kidins220. Therefore, currently the cytoskeleton remodelling 
which is driven through Kidins220 is best characterised in 
immature dendritic cells (10). Upon migration onto extracel-
lular matrices, highly polarized immature dendritic cells 
change stage, from monopolar to symmetrical bipolar. During 
this process, Kidins220 is highly expressed at dendritic cell 
polarized membrane edges where F-actin localises (10). 
Further immunocytochemistry analysis has revealed that 
Kidins220 expression is concentrated around proteins which 
are associated with the raft compartment (10). Lipid rafts 
are microdomains of the cell plasma membrane and contain 
distinctive protein and lipid constituents, which are involved in 
the regulation of signalling transduction. Chemically induced 
disruption of lipid rafts resulted in the loss of Kidins220 from 
the enriched polarized edges, indicating a regulatory role of 
Kidins220 in cell morphology changes and motility (10,11). 
Kidins220 has also been observed at the neuromuscular junc-
tion suggesting that Kidins220 also plays a role in muscle 
development (12). Luo et al  proposed a possible model in 
which Kidins220 bridges a link between α-syntrophin and 
Eph4, thus contributing to the regulation of synapse formation 
and plasticity. Further evidence has shown that this interaction 
occurs through α-syntrophin induction of Kidins220 clustering 
at the neuromuscular junction. This Kidins220-mediated 
localisation subsequently results in the activation of Eph4 
which in turn stimulates postsynaptic signal cascades (12). 
By interacting with a variety of proteins, Kidins220 regulates 
neuronal activities. For instance, kinesin light chain 1 (KLC1) 
is a binding partner for Kidins220. In PC-12 cells, it was 
demonstrated that after nerve growth factor (NGF) stimula-
tion, intracellular trafficking of Kidins220, from trans-Golgi 
network to the plasma membrane, relied on KLC1-based 
transport mechanism (13).
4. Interacting partners
Kidins220 binds with a variety of interacting partners and 
is involved in various neuronal activities (Fig. 1). Kidins220 
acts as a downstream substrate of protein kinase D (PKD), 
where enhanced PKD activity stimulates phosphorylation of 
Kidins220 at serine 919 in PC12 cells (1). The most significant 
role identified of Kidins220 is to act as a downstream substrate 
of Trk receptor tyrosine kinase. Kidins220 is currently the only 
known membrane-associated protein which interacts with both 
Trk and p75 neurotrophin receptors, often forming a ternary 
complex (14). Kong et al identified that within hippocampal 
neurons which were stimulated by neurotrophin, rapid phos-
phorylation of Kidins220 was exhibited indicating Kidins220 
as a downstream target of neurotrophin (9). Further research 
by Arévalo et al revealed that rapid tyrosine phosphorylation 
of Kidins220 was induced in primary neurons after treat-
ment with neurotrophin. They further identified that it was 
a specific site Tyr1096 which activated mitogen-activated 
protein kinase (MAP kinase) activity through phosphorylated 
Kidins220 recruits CrkL, an upstream component of the 
C3G-Rap1-MAP kinase cascade, in a neutrophin dependent 
manner. This sustained MAP kinase activation was affected 
in PC-12 cells by a mutation within Tyr1096 affecting cell 
differentiation (15). Notably, it appeared that the mutation or 
Figure 1. Structure of Kidins220 and its binding interaction partners. Schematic 
structure of Kidins220 scaffold protein. An archetypal Kidins220 scaffold 
protein contains multiple protein binding domains and post-translational 
modified sites, through which Kidins220 coordinates signal transduction of 
various pathways, such as Trk and MAPK. The scaffolding role of Kidins220 
appears to be directed based on the different binding partners within the 
protein. Kidins2202, kinase D-interacting substrate of 220 kDa/ankyrin 
repeat-rich membrane spanning; SAM, sterile α motif; MAP, microtubule-
associated protein; KIM, kinase light chain (KLC)-interacting motif; PDZ, 
PSD-95, Dlg, ZO-1-binding motif; Trks, tropomyosin receptor kinase; NGFR, 
nerve growth factor receptor; VEGFR, vascular endothelial growth factor 
receptor.
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interference of Kidins220 only reduced neurotrophin-elicited 
signalling in the ERK pathway, suggesting an important role 
played by Kidins220 in mediating neurotrophin-induced signal 
transduction via the MAP kinase pathway (16). Kidins220 was 
also phosphorylated in NG108-15 cells following exposure 
to ephrin B, suggesting it acts downstream of ephrin recep-
tors (9).
Based on yeast two-hybrid screening, Kidins220 activity 
in muscle has been linked to the binding of α-syntrophin, 
via the PDZ domain. Kidins220 displays clustering in 
response to increased expression levels of α-syntrophin 
which further augments EphA4 signalling (12). In nuclear 
factor-κB (NF-κB) signalling induced by brain-derived 
neurotrophic factor (BDNF), a neurotrophin with prefer-
ence for targeting tropomyosin receptor kinase B (TrkB), 
Sniderhan et al demonstrated that silencing of Kidins220 or 
targeting the Kidins220-TrkB interaction abolished NF-κB 
signalling elicited by BDNF. Further elucidation of the BDNF-
induced interaction between Kidins220 and TrkB suggested 
that NF-κB signalling was facilitated by the activation of MAP 
kinase and IκB kinase (IKK) leading to the phosphorylation of 
RelA (17).
Septin 5, which has been implicated in cytoskeleton reor-
ganisation, has also been identified as an interacting partner 
of Kidins220 and may serve as a regulatory element for 
intracellular signalling activities (18). The results of a yeast 
two-hybrid screen and co-immunoprecipitation revealed that 
these two proteins are co-localized in hippocampal neurons. 
In PC12 cells, Kidins220 and Septin5 are expressed on the 
tips of growing neurites induced by NGF. Andreazzoli et al 
performed a screening for brain cDNA products from a phage 
display library and demonstrated an interaction between the 
PDZ-domain of Kidins220 and Pdzrn3, a protein comprised 
of a PDZ-domain and RING-finger. The co-localization of 
Kidins220 and Pdzrn3 has been observed in PC12 cells in 
growing neurites induced by NGF (19).
5. Kidins220, neurite outgrowth, survival and death
Kidins220 binds and activates RhoGEF Trio in ankyrin-repeats. 
In NGF-differentiated PC12 cells, Neubrand et al found that 
Kidins220 and Trio were colocalized in specific sites with 
F-actin and Rac1 (20). Trio is a RhoGEF for Rac1, RhoG and 
RhoA and plays an important role in the regulation of neurite 
outgrowth. They identified that in PC12 cells, overexpression 
of Kidins220 in ankyrin repeats inhibited NGF-dependent 
neurite outgrowth regulated by Trio, and a similar mechanism 
was also verified in hippocampal neurons (20). Bracale et al 
conducted a yeast two-hybrid screen and identified KLC1, the 
subunit of kinesin1, as the interacting partner of Kidins220. 
In NGF-induced PC12 cells, Kidins220 colocalising with 
kinesin1 was impacted by the overexpression of KIM, a 
KLC-interacting motif in Kidins220, ultimately interfering 
with neurite outgrowth (13). Base on the preferential binding 
of NGF and TrkA neurotrophin receptor, López-Benito et al 
identified a novel signalling pathway, mediated by NGF 
which includes TrkA, Kidins220, synembryn-B and Rac1, 
implicated in neuronal secretion in PC12 cells (21). Rac1 is 
the downstream target of Kidins220 and synembryn-B, which 
themselves directly interact. NGF-mediated secretion is 
blocked by the overexpression of Kidins220 and synembryn-B; 
however, basal secretion was unaffected (20). The secretion 
defects caused by high levels of Kidins220 were rescued by the 
expression of dominant-negative Rac1 (21).
6. Kidins220 in neuronal polarity, synaptic plasticity and 
neurotransmission
The diverse function of neurons depends on the highly polar-
ised morphology regulated by axon and dendrites. Kidins220 
interacts with tubulin (SCG10 and SCLIP) and microtubule-
associated proteins (MAPs) to regulate neuronal polarity. As 
members of MAPs, the phosphorylation of MAP1b and stath-
mins were impaired following the downregulation of Kidins220. 
Furthermore, downregulation of Kidins220 also led to the 
aberrant dendritic arbors and extensions of the longer axon (22). 
AMPARs produce mature glutamatergic synapse by targeting 
the cell surface during neuronal development (23). As a subunit 
of AMPAR, GluA1 can be upregulated when Kidins220 is 
downregulated. Thus, in the process of neuronal mutation and 
synapse formation, the decreased expression of Kidins220 results 
in enhanced GLuA1 expression and thus the establishment of a 
strong synaptic connection (7). In mature neuronal cultures, there 
is also a relevant evidence of interplay between Kidins220 and 
NMDA receptors. Upon overstimulation of NMDA receptors, 
such as during excitotoxicity, or when neurons are depolarised, 
Ca2+ activity-dependent Ca2+ influx, through NMDA receptors 
leads to a decrease in Kidins220 levels through both transcrip-
tional downregulation and protein cleavage by calpain (21). 
Because Kidins220 knockdown causes a decrease in the amount 
of phosphorylated MAPK, a reduction in the expression of 
Kidins220 may contribute to neuronal death through a decrease 
in MAPK signalling (7). In hippocampal neurons, the decreased 
expression of Kidins220 prohibited GABAergic neurotransmis-
sion, whereas the overexpression of Kidins220 reverses this 
effect. Furthermore, the GABAergic neurotransmission regu-
lated by Kidins220 is through a presynaptic mechanism  (24). 
In hippocampal neurons with overexpression of Kidins220 
increased long-term potentiation was impaired when calpain 
was prohibited (25). Sutachan et al found that Kidins220 is 
implicated in regulating the inhibition of neurotransmission (24).
7. Kidins220 and vascular development
Cesca et al addressed the potential role of Kidins220 in 
vascular development due to its targeting of and interaction 
with VEGFRs. Mice with a Kidins220 knockdown phenotype 
were found to present with cardiovascular abnormalities. These 
abnormalities appeared to be caused by impaired VEGF signal-
ling pathways induced by lack of Kidins220 (26). Interestingly, 
Kidins220 interacts with VEGFR2 and VEGFR3 but not 
Nrp1, although both VEGFR2 and VEGFR3 are co-receptors 
of Nrp1 in endothelial cells. VEGF signalling is one of the 
key pathways in the process of angiogenesis especially medi-
ated by VEGF/VEGFR2, Kidins220 was demonstrated to 
interact with VEGFR2 constitutively (27). However, mice 
with more severe vascular abnormalities were detected in the 
model with the knockdown of VEGF, VEGRFs, Nrp1 than 
Kidins220-/- itself (26), suggesting that Kidins220 regulation 
of angiogenesis may be limited.
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8. Kidins220 and immunomodulation
Apart from the role of Kidins220 in modulating neuronal 
activities, it also contributes to immunomodulation along with 
B cells and T cells. Kidins220 is expressed at the uropod of 
T lymphocytes and has been shown to be co-immunoprecip-
itated with ICAM-3 and caveolin-1 (28). Notably, in primary 
T lymphocytes, the colocalisation of Kidins220 and ICAM-3 
is increased with the induction of morphological polariza-
tion. In contrast, Kidins220 displays different distribution 
upon change in cell polarity, and colocalisation with ICAM-3 
becomes disrupted. The identification of Kidins220 in the 
regulation of T-cell motility was indicated in a Kidins220-
knockdown model of human polarized T-cell lines in which 
the basal and stromal cell-derived factor-1α-induced migra-
tion was increased following knockdown of Kidins220 (28). 
Based on mass spectrometry, Deswal et al demonstrated the 
interaction between Kidins220 and B-Raf in T lymphocytes. 
In immunoprecipitation and proximity ligation assays, the 
sustained ERK signalling relied on Kidins220 induced by 
T cell receptor (TCR) (29). Furthermore, Fiala et al reported 
that Kidins220 interacted with stimulated B cell antigen 
receptor (BCR), in an enhanced Src kinase-independent 
manner via BCR stimulation. In a B cell-specific Kidins220 
knockdown (B-KO) mouse model, Kidins220 coupled the 
BCR to PLCγ2, Ca2+, and ERK signalling and reduced the 
activation of B cells regulated by BCR in vitro and in vivo. 
The role of Kidins220 involved in the PLCγ2 pathway was 
supported by a 6-fold reduction in B cells with positive λ light 
chain (30).
9. Kidins220 in tumours
Several observations support the importance of Kidins220 
in cancer pathogenesis in addition to its function in neuronal 
activity. A growing body of evidence points to the deregula-
tion of Kidins220 at the cell level affecting cell proliferation, 
invasion, migration, and apoptosis, playing an important role in 
tumour formation and metastasis (Table I). Overexpression of 
the Kidins220 gene was initially reported in melanoma and was 
found to be associated with shorter overall survival. As a cuta-
neous malignancy, melanoma ontogenetically originates from the 
neural crest and increased expression of Kidins220 was detected 
in melanoma cell lines (31,32). Immunohistochemical staining of 
different surgical specimens subsequently revealed significantly 
increased expression of Kidins220 in primary and metastatic 
melanoma tissues with depths >1.0 mm compared with benign 
tumour tissues.
Kidins220 lies upstream of the BRAF gene that encodes 
proteins as part of the RAS/MAPK signalling pathway control-
ling several important cell functions. The overexpression of 
Kidins220 resulting in sustained activation of MEK/ERK 
signalling rather than BRAF mutation, has been identified as 
leading to acral lentiginous melanoma tumourigenesis. On 
the other hand, high levels of Kidins220 also enhance ultra-
violet radiation B (UVB) (290-320 nm)-induced apoptosis in 
melanoma cells via targeting the activated ERK signalling 
pathway (31). The inhibition of melanoma cell migration and 
invasion associated with Kidins220 knockdown indicates that 
Kidins220 can promote tumour migration/invasion through 
MEK/ERK signalling (31,32). Taken together, Kidins220 
expression is regarded as a predictor with which to evaluate 
melanoma patient outcomes, and its physiologic characteris-
tics also provide evidence for targeted therapy by inhibiting 
the Kidins220/MEK/ERK/MAPK signalling pathways.
The regulatory role of Kidins220 in cancer development 
is tumour specific. For example, Kidins220 exerts different 
regulatory mechanisms to the MARK signalling pathway 
in neuroblastoma tumours. Rogers and Schor first reported 
that neuroblastoma tumours overexpress Kidins220, and that 
its forced overexpression promotes NGF-stimulated MAPK 
signalling activity, but not BDNF driven activation of MAPK 
signalling. Unlike melanoma, Kidins220 knockdown did not 
affect the survival of neuroblastoma cells under oxidative stress 
Table I. Alteration of Kidins220 in tumourigenesis and the related signalling pathway.
Tumour type Alteration Effect Signalling pathways (Refs.)
Cutaneous Increased expression Melanoma formation,  MEK/ERK (31,32) 
melanoma  migration and invasion signalling pathway
Neuroblastoma Increased expression Proliferation p21/cyclin D1 (35)
  NGF-regulated signalling  (33)
  Transition from N-type to S-type  (34)
Castration-resistant Increased expression Angiogenesis VEGF/VEGFR and (36)
prostate cancer   PI13K/AKT
(CRPC)   signalling pathways
Ph-like acute  Gene fusion with PAX5 Proliferation and survival ERK signalling pathway (44)
lymphoblastic 
leukemia (ALL)
Pediatric high-grade Intragenic copy n.d. n.d. (45)
glioma number breakpoint
Kidins220, kinase D-interacting substrate of 220 kDa; VEGFR, vascular endothelial growth factor receptors; NGF, nerve growth factor; n.d., 
not determined.
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within 24 h. Furthermore, loss of Kidins220 did not affect 
migration of neuroblastoma cells (33). During development, 
neuroblastoma undergoes a morphologic transition between 
Schwannian stromal (S-type) cells and neuroblastic (N-type) 
cells. S-type cells are highly adhesive to extracellular matrix 
(ECM) and are non-invasive, whereas N-type are less adhesive 
and highly invasive. DCX and STMN2 markers for neuronal 
lineage appear to be reduced in Kidins220-deficient N-type 
cells, whereas S-type cells containing low levels of Kidins220 
(but not Kidins220 depletion) expressed considerable levels 
of both DCX and STMN2. This suggests an essential role of 
Kidins220 in regulating morphologic alteration in neural crest 
tumour cells (34). Jung et al generated Kidins220-knockdown 
neuroblastoma cell lines to determine whether Kidins220 is 
involved in cell proliferation. They found that wild-type cells 
were 1.8-fold higher in number than the matching knockdown 
cells on the fourth day of culture. Further analysis revealed that 
the decreased growth rate of Kidins220-knockdown neuro-
blastoma cells was due to cell cycle arrest at the G1 phase, 
which was accompanied with decreased expression of both 
cyclin D1 and CDK4, and also an upregulation of p21. This 
suggests that Kidins220 can coordinate the cell cycle through 
regulation of p21-cyclinD1/CDK4 (35).
A recent study reported that Kidins220 is a direct target 
of miR-4638-5P. miR-4638-5P has been related to the growth 
of castration-resistance prostate cancer (CRPC) in vivo and 
in vitro. Wang et al discovered a significant downregulation 
of miR-4638-5P in CRPC. High expression of Kidins220 
was detected in both CRPC cell lines and tissues compared 
with androgen-dependent prostate cancer (ADPC). Western 
blot analysis showed that only Kidins220 expression was 
significantly reduced in PC3 and DU145 cells in the presence 
of miR-4638-5P. Knockdown of Kidins220 led to reduced 
proliferation and growth of CRPC cells in vitro and in vivo. 
Furthermore, miR-4638-5P and Kidins220 regulated prostate 
cancer (PCa)-associated angiogenesis. Kidins220 knockdown 
or overexpression of miR-4638-5P resulted in similar inhibition 
of endothelial cell growth and the formation of vasculogenic 
mimicry. Their further molecular analysis indicated that 
pCDH-miR-4638-5p sponge, a competitive miRNA inhibitor, 
caused an increase in expression of VEGF, PI3K and AKT in 
androgen-independent PCa cells, whereas all three molecules 
were reduced in Kidins220-knockdown PCa cells, suggesting 
that both miR-4638-5P and Kidins220 may be involved 
in androgen-independent PCa-associated angiogenesis. 
Interestingly, a reduced level of cell growth and angiogen-
esis were also observed in AKT-knockdown cells which is 
in accordance with the result from Kidins220-knockdown 
cells. Taken together, loss of miR-4638-5 may result in the 
activation of Kidins220 and promote neoangiogenesis and 
androgen-independent PCa growth through the regulation of 
VEGF/VEGFR2 and PI3K/AKT signalling pathways (36).
As previously mentioned, Kidins220 is the substrate of 
PKD. At the trans-Golgi network, the family members of PKD 
were found to regulate secretory transport (37). PKD1 plays 
an important role in stimulating the secretion of neurotensin, 
a gut peptide, which modulates gastrointestinal functions 
such as secretion and growth, as well as being involved in the 
proliferation of neurotensin receptor-positive cancers (38-40). 
In human carcinoid BON cells, a novel endocrine cell line 
that is derived from a human pancreatic carcinoid tumour, 
Kidins220 and PKD2 regulated the secretion of neuro-
tensin (41,42). Further interest is the observation that in BON 
cells, Kidins220, PKD1 and PKD2 present the same localiza-
tion pattern as neurotensin vesicles, and also co-exist with 
neurotensin vesicles. Interestingly the overexpression of PKD1 
nullified Kidins220 expression and neurotensin secretion in 
BON cells (42). Thus, the PKD/Kidins220 signalling pathway 
provides evidence for their critical role in the regulation of 
neurotensin hormone secretion. Since neurotensin is involved 
in secretion and inflammation in both normal and tumour 
cell growth, the PKD/Kidins220 pathway and neurotensin-
containing vesicles are considered as a novel drug target for 
clinical application (42,43).
Apart from its role in solid tumours, a recent study also 
demonstrated a gene fusion of PAX5 and Kidins220, which 
leads to leukemogenesis by inhibiting B lymphocyte differ-
entiation. Kidins220-mediated activation of the ERK pathway 
may contribute to the increased cell proliferation and the 
survival of leukemic cells (44).
Controversially, Kidins220 plays a different role in glioma, 
which was demonstrated in a profiling study of its function as 
a tumour suppressor in pediatric high-grade glioma (45).
10. Conclusion and perspective
Kidins220 is involved in the regulation of diverse cellular 
activities, particularly in neural differentiation and cyto-
skeleton remodelling (13). Its different domains mediate the 
function of Kidins220 as well as act as a platform for protein-
protein interactions, intracellular signalling and protein 
transportation. Dysregulation of Kidins220 is evident in 
several malignancies. Kidins220 binds to Trio, tubulin, SCG10 
and SCLIP to modulate actin and microtubule cytoskeleton, 
which is critical in the coordination of cellular processes, such 
as cell migration, cell polarity and cell cycle progression (46). 
Tumour cell migration and invasion require the remodelling of 
the cell cytoskeleton. Reorganization of the actin cytoskeleton 
that enables dynamic cell elongation and directional motility 
is also found in epithelial-mesenchymal transition (EMT), a 
critical process involved in tumour development (47). Further 
investigation will shed light on the role played by Kidins220 
in dynamic arrangement of the cytoskeleton and EMT, and 
its implication in tumourigenesis and cancer progression. 
Kidins220 regulates cell survival and death through MAPK 
signalling after the binding of neurotrophins and Trk recep-
tors (7). Since dysregulation of MAPK signalling is linked to 
tumourigenesis in several types of cancer and inhibition of 
the MAPK signalling pathways is critical for the effectiveness 
of anticancer agents, it is necessary to gain insight into the 
corresponding involvement of Kidins220 (48,49). Targeting 
its specific multiple domains such as the proline-rich domain 
and transmembrane segments may provide the possibility 
of more precise targeting. In addition to its involvement in 
VEGF/VEGFR-regulated angiogenesis, Kidins220 has been 
shown as a target gene of miR-4638-5p and its overexpres-
sion has been observed in androgen-independent PCa and also 
tumour-associated angiogenesis (36). However, its potential for 
targeted therapy in these malignancies and tumour-associated 
angiogenesis warrants further investigation.
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